Live Breaking News & Updates on செல் வரி|Page 3

Stay updated with breaking news from செல் வரி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biologics Safety Testing Market worth $6.2 billion by 2026 - Exclusive Report by MarketsandMarkets


Biologics Safety Testing Market worth $6.2 billion by 2026 - Exclusive Report by MarketsandMarkets
Biologics Safety Testing Market
by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test) - Global Forecast to 2026 , published by MarketsandMarkets, the global market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.
Browse in-depth TOC on Biologics Safety Testing Market
142 - Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
The growth of the global biologics safety market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. ....

United States , Kostenloser Wertpapierhandel , Asia Pacific , Aashish Mehra , Charles River Laboratories Inc , Product Service Consumables , Product Service Assays , Biotechnology Market Research Reports Consulting , Thermo Fisher Scientific Inc , Research Insight , Safety Testing Market , Monoclonal Antibodies , Gene Therapy Products , Test Type , Sterility Test , Safety Testing , Biologics Safety Testing , Sample Pages , Charles River Laboratories , Thermo Fisher Scientific , Wuxi Apptec , Eurofins Scientific , Adjacent Markets , Biotechnology Market Research Reports , Related Reports , Testing Market ,

Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate


Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate
 
BERLIN, Germany, April 26, 2021 / B3C newswire / ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
ProBioGen will now advance the development of Asher s lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck™ which greatly accelerates time-to-clinic.
Asher Biotherapeutics, a biotech company located in the San Francisco Bay Area, is developing cis-targeted immunotherapies with a new level of selectivity for the potential treatment of cancer, autoimmune and infectious diseases. ....

Gabriele Schneider , Sandy Yeung , Asher Biotherapeutics , Asher Biotherapeutics Inc , Cell Line Development , San Francisco Bay Area , Chief Operations Officer , Cell Line , Cell Culture Techniques , Culture Media , Cell Proliferation , Biological Products , கேப்ரியல் ஶ்நைடர் , ஆண்டி யியுங் , செல் வரி வளர்ச்சி , சான் பிரான்சிஸ்கோ வளைகுடா பரப்பளவு , தலைமை செயல்பாடுகள் அதிகாரி , செல் வரி , செல் கலாச்சாரம் நுட்பங்கள் , கலாச்சாரம் மீடியா , உயிரியல் ப்ராடக்ட்ஸ் ,